Doctor of Osteopathy Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Daniel Brunner

Interventional Pain Medicine Neenah, WI Doctor of Osteopathy

NPI 1811492622 CMS profile 7221366

1205 W American Dr, Neenah, WI 54956

Open in the dashboard

General payments

$23,804

38 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Brunner of Neenah, WI is reported in the CMS Open Payments database as having received $23,804 across 38 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $38 2
2024 General $166 4
2023 General $10,801 9
2022 General $12,697 21
2021 General $102 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Brunner
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Daniel Brunner were reported at $38. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Daniel Brunner Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $102 $552 $167–$1,554 $132
2022 $12,697 $605 $187–$1,924 $149
2023 $10,801 $671 $195–$1,915 $160
2024 $166 $684 $206–$1,837 $164
2025 $38 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $22,071 16 payments
  2. Abbott Laboratories $608 7 payments
  3. SPR Therapeutics, Inc $274 4 payments
  4. Nevro Corp. $255 2 payments
  5. Painteq LLC $237 1 payment
  6. Vertos Medical, Inc. $150 1 payment
  7. Heron Therapeutics, Inc. $69 1 payment
  8. Stryker Corporation $49 2 payments
  9. AbbVie, Inc. $34 1 payment
  10. Bioventus LLC $24 1 payment
  11. Other $33 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Grant $20,000 2 payments
  2. Food and Beverage $2,031 28 payments
  3. Travel and Lodging $1,773 8 payments
Products named General payments · program years 2021–2025
  1. SYNCHROMEDII $20,000 2 payments
  2. INTELLIS ADAPTIVESTIM $2,038 13 payments
  3. PROCLAIM Neuromodulation $558 6 payments
  4. SPRINT PNS System $274 4 payments
  5. PAINTEQ $237 1 payment
  6. mild Device Kit $150 1 payment
  7. Senza $148 1 payment
  8. Omnia $107 1 payment
  9. Zynrelef $69 1 payment
  10. PROCLAIM Neuromodulation $50 1 payment
  11. Other $219 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

263

Median for Pain Management: 951

Drug cost

$2,353

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 97 $670
Celecoxib Generic 12 $534
Pregabalin Generic 27 $467
Methocarbamol Generic 17 $225
Tramadol Hcl Generic 43 $213
Tizanidine Hcl Generic 23 $132
Methylprednisolone Generic 12 $70
Meloxicam Generic 13 $26
Diazepam Generic 19 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$59,395

Of which drugs: $472

Medicare patients

185

Average age 71

Services billed

2,821

106 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 66%
Depression 31%
Ischemic heart disease 27%
Diabetes 24%
Chronic kidney disease 22%
COPD 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 67 330 $239
Injection, methylprednisolone acetate, 1 mg J1010 Office 23 1,480 $150
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 22 250 $22
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 51 131 $13
Infusion, normal saline solution, 250 cc J7050 Office 16 17 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record